Genmab Reports Strong Q3 2025 DARZALEX® Sales

An update from Genmab ( (GMAB) ) is now available.

On October 14, 2025, Genmab A/S announced that the net sales of DARZALEX® (daratumumab) for the third quarter of 2025 totaled USD 3,672 million, with USD 2,088 million from the U.S. and USD 1,584 million from the rest of the world. Genmab receives royalties on these sales from Johnson & Johnson, which holds the exclusive worldwide license to develop, manufacture, and commercialize daratumumab. This announcement highlights Genmab’s strong market presence and the significant impact of DARZALEX® on its financial performance.

The most recent analyst rating on (GMAB) stock is a Buy with a $49.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.

Average Trading Volume: 1,696,512

Technical Sentiment Signal: Buy

Current Market Cap: $20.58B

For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.